Summit outlines phase 3 program for CDI antibiotic ridinilazole
After constructive negotiations with several regulators including the US Food and Drug Administration and European Medicines Agency, Summit said it will design a trial intended at assessing the superiority of ridinilazole over the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.